rogaratinib (BAY 1163877)

News alerts, weekly reports and conference planners

Company:

Bayer

Drug class:

FGFR inhibitor

Related drugs:

FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B
FGFR3 overexpression	Urothelial Cancer	FGFR3 overexpression	Urothelial Cancer	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2
FGFR1 overexpression	Urothelial Cancer	FGFR1 overexpression	Urothelial Cancer	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2
FGFR1 expression	Urothelial Cancer	FGFR1 expression	Urothelial Cancer	BAY 1163877 Sensitive: C2 – Inclusion Criteria BAY 1163877 Sensitive : C2	BAY 1163877 Sensitive: C2 – Inclusion Criteria BAY 1163877 Sensitive : C2
FGFR3 overexpression	Head and Neck Cancer	FGFR3 overexpression	Head and Neck Cancer	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR expression	Urothelial Cancer	FGFR expression	Urothelial Cancer	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR3 expression	Urothelial Cancer	FGFR3 expression	Urothelial Cancer	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR overexpression	Urothelial Cancer	FGFR overexpression	Urothelial Cancer	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR overexpression	Non Small Cell Lung Cancer	FGFR overexpression	Non Small Cell Lung Cancer	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR overexpression	Squamous Cell Carcinoma of Head and Neck	FGFR overexpression	Squamous Cell Carcinoma of Head and Neck	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR3 overexpression	Lung Non-Small Cell Squamous Cancer	FGFR3 overexpression	Lung Non-Small Cell Squamous Cancer	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3
FGFR2 overexpression	Lung Non-Small Cell Squamous Cancer	FGFR2 overexpression	Lung Non-Small Cell Squamous Cancer	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3
FGFR1 overexpression	Lung Non-Small Cell Squamous Cancer	FGFR1 overexpression	Lung Non-Small Cell Squamous Cancer	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3
FGFR3 expression	Urothelial Cancer	FGFR3 expression	Urothelial Cancer	atezolizumab + BAY 1163877 Sensitive: C3 – Early Trials atezolizumab + BAY 1163877 Sensitive : C3	atezolizumab + BAY 1163877 Sensitive: C3 – Early Trials atezolizumab + BAY 1163877 Sensitive : C3
FGFR1 expression	Urothelial Cancer	FGFR1 expression	Urothelial Cancer	atezolizumab + BAY 1163877 Sensitive: C3 – Early Trials atezolizumab + BAY 1163877 Sensitive : C3	atezolizumab + BAY 1163877 Sensitive: C3 – Early Trials atezolizumab + BAY 1163877 Sensitive : C3
FGFR3 overexpression	Urothelial Cancer	FGFR3 overexpression	Urothelial Cancer	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR1 overexpression	Urothelial Cancer	FGFR1 overexpression	Urothelial Cancer	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR1 amplification	Hormone Receptor Positive Breast Cancer	FGFR1 amplification	Hormone Receptor Positive Breast Cancer	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3
FGFR2 amplification	Hormone Receptor Positive Breast Cancer	FGFR2 amplification	Hormone Receptor Positive Breast Cancer	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3
FGFR1 overexpression	Hormone Receptor Positive Breast Cancer	FGFR1 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3
FGFR2 overexpression	Hormone Receptor Positive Breast Cancer	FGFR2 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3
FGFR3 positive	Squamous Cell Carcinoma of Head and Neck	FGFR3 positive	Squamous Cell Carcinoma of Head and Neck	BAY 1163877 Sensitive: D – Preclinical BAY 1163877 Sensitive : D	BAY 1163877 Sensitive: D – Preclinical BAY 1163877 Sensitive : D
FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck	FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck	BAY 1163877 Sensitive: D – Preclinical BAY 1163877 Sensitive : D	BAY 1163877 Sensitive: D – Preclinical BAY 1163877 Sensitive : D

rogaratinib (BAY 1163877)

Associations
(23)

Associations
(23)

rogaratinib (BAY 1163877)

Associations(23)

Associations(23)

Associations
(23)

Associations
(23)